[1]辅容,卢琳,龚凤英,等.库欣病的分子机制及靶向药物[J].国际内分泌代谢杂志,2016,36(06):400-403.[doi:10.3760/cma.j.issn.1673-4157.2016.06.11]
　Fu Rong,Lu Lin,Gong Fengying,et al.Molecular mechanisms of Cushing’s disease and targeted drug[J].International Journal of Endocrinology and Metabolism,2016,36(06):400-403.[doi:10.3760/cma.j.issn.1673-4157.2016.06.11]
点击复制

库欣病的分子机制及靶向药物()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
36
期数:
2016年06期
页码:
400-403
栏目:
综述
出版日期:
2016-11-20

文章信息/Info

Title:
Molecular mechanisms of Cushing’s disease and targeted drug
作者:
辅容; 卢琳; 龚凤英; 潘慧; 朱慧娟; 陆召麟
100730 北京,中国医学科学院,北京协和医学院,北京协和医院内分泌科,国家卫生和计划生育委员会内分泌重点实验室
Author(s):
Fu Rong;  Lu Lin;  Gong Fengying;  Pan Hui;  Zhu Huijuan;  Lu Zhaolin.
Department of Endocrinology, Key Laboratory of Endocrinology of National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing 100730, China
关键词:
促肾上腺皮质激素分泌垂体腺瘤;  靶向治疗;  表皮生长因子;  细胞周期蛋白依赖激酶2;  热休克蛋白90
Keywords:
Adrenocorticotropin hormonesecreting pituitary adenoma;  Targeted therapy;  Epidermal growth factor;  Cyclin-dependent kinase 2;  Heat-shock protein 90
DOI:
10.3760/cma.j.issn.1673-4157.2016.06.11
摘要:
由垂体瘤分泌过多的促肾上腺皮质激素导致的库欣综合征,又称为库欣病,首选治疗为手术治疗,放射治疗和药物治疗为其辅助治疗,但疗效均有限。近年来关于库欣病发病机制的研究集中于调控细胞增殖的异常蛋白表达和调控激素分泌的异常信号转导,靶点主要为表皮生长因子受体(EGFR)、细胞周期蛋白E(CDK2/Cyclin E)和热休克蛋白90(HSP90),相应的靶向药物吉非替尼、roscovitine和水飞蓟素均能有效减小肿瘤体积,降低促肾上腺皮质激素水平。
Abstract:
Cushing’s disease, also called Cushing’s syndrome is due to excessive secretion of adrenocorticotropin hormone(ACTH)caused by pituitary adenoma. Surgery is recommended as the first-line therapy, while radiotherapy and medicine are adjunctive therapies. But effects of these therapies are limited. Recently, the studies on the pathogenesis of Cushing’sdisease have focused on the abnormal protein expressions of cell proliferation and dysregulated signal transductions of hormone secretion. Targets includes epidermal growth factor receptor, cyclin-dependent kinase 2/Cyclin E and heat-shock protein 90. Corresponding targeted drugs such as gefitinib, roscovitine, silibinin are proven to be effective to reduce the volume of the tumor and the level of ACTH.

参考文献/References:

[1] Brue T, Castinetti F. The risks of overlooking the diagnosis of secreting pituitary adenomas[J].Orphanet J Rare Dis, 2016,11(1):135. DOI:10.1186/s13023-016-0516-x.
[2] Bolland MJ, Holdaway IM, Berkeley JE,et al. Mortality and morbidity in Cushing’s syndrome in New Zealand[J].Clin Endocrinol(Oxf), 2011,75(4):436-442. DOI: 10.1111/j.1365-2265.2011.04124.x.
[3] Dekkers OM, Biermasz NR, Pereira AM,et al. Mortality in patients treated for Cushing’s disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma[J].J Clin Endocrinol Metab,2007,92(3):976-981.DOI:10.1210/jc.2006-2112.
[4] Tritos NA, Biller BM. Cushing’s disease[J].Handb Clin Neurol, 2014,124:221-234.DOI:10.1016/B978-0-444-59602-4.00015-0.
[5] Petersenn S, Beckers A, Ferone D,et al. Therapy of endocrine disease: outcomes in patients with Cushing’s disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence[J].Eur J Endocrinol, 2015,172(6):R227-R239. DOI: 10.1530/EJE-14-0883.
[6] van der Pas R, de Herder WW, Hofland LJ,et al. Recent developments in drug therapy for Cushing’s disease[J].Drugs,2013,73(9):907-918. DOI: 10.1007/s40265-013-0067-6.
[7] Castinetti F, Morange I, Conte-Devolx B,et al. Cushing’s disease[J].Orphanet J Rare Dis, 2012,7:41.DOI:10.1186/1750-1172-7-41.
[8] Kong YG, Ren ZY, Su CB,et al. Elevated soluble epidermal growth factor receptor level in pituitary adenoma and carcinoma[J].Chin Med Sci J, 2004,19(3):199-202.
[9] Fukuoka H, Cooper O, Ben-Shlomo A,et al. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas[J].J Clin Invest, 2011,121(12):4712-4721. DOI: 10.1172/JCI60417.
[10] Onguru O, Scheithauer BW, Kovacs K,et al. Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas[J].Mod Pathol, 2004,17(7):772-780.DOI:10.1038/modpathol.3800118.
[11] Theodoropoulou M, Arzberger T, Gruebler Y,et al. Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells[J].J Endocrinol, 2004,183(2):385-394.DOI:10.1677/joe.1.05616.
[12] Wondisford FE. A new medical therapy for Cushing disease [J].J Clin Invest, 2011,121(12):4621-4623.DOI:10.1172/JCI61127.
[13] Ferone D, Pivonello C, Vitale G,et al. Molecular basis of pharmacological therapy in Cushing’s disease[J].Endocrine, 2014,46(2):181-198.DOI:10.1007/s12020-013-0098-5.
[14] Reincke M, Sbiera S, Hayakawa A,et al. Mutations in the deubiquitinase gene USP8 cause Cushing’s disease[J].Nat Genet, 2015,47(1):31-38. DOI: 10.1038/ng.3166.
[15] Ma ZY, Song ZJ, Chen JH,et al. Recurrent gain-of-function USP8 mutations in Cushing’s disease[J].Cell Res, 2015,25(3):306-317. DOI: 10.1038/cr.2015.20.
[16] Perez-Rivas LG, Theodoropoulou M, Ferraù F,et al. The gene of the ubiquitin-specific protease 8 is frequently mutated in adenomas causing Cushing’s disease[J].J Clin Endocrinol Metab, 2015,100(7):E997-E1004. DOI: 10.1210/jc.2015-1453.
[17] Liu YT, Hao XZ, Li JL,et al. Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China[J].Thorac Cancer,2015,6(5):636-642.DOI:10.1111/1759-7714.12267.
[18] Jordan S, Lidhar K, Korbonits M,et al. Cyclin D and cyclin E expression in normal and adenomatous pituitary[J].Eur J Endocrinol, 2000,143(1):R1-R6.
[19] Mu �瘙 塂 at M, Morris DG, Korbonits M,et al. Cyclins and their related proteins in pituitary tumourigenesis[J].Mol Cell Endocrinol, 2010,326(1-2):25-29. DOI: 10.1016/j.mce.2010.03.017.
[20] Liu NA, Jiang H, Ben-Shlomo A,et al. Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase(CDK)inhibitor[J].Proc Natl Acad Sci U S A, 2011,108(20):8414-8419. DOI: 10.1073/pnas.1018091108.
[21] Roussel-Gervais A, Bilodeau S, Vallette S,et al. Cooperation between cyclin E and p27(Kip1)in pituitary tumorigenesis[J]. Mol Endocrinol, 2010,24(9):1835-1845. DOI: 10.1210/me.2010-0091.
[22] Fukuoka H. New potential targets for treatment of Cushing’s disease: epithelial growth factor receptor and cyclin-dependent kinases[J].Pituitary,2015,18(2):274-278.DOI:10.1007/s11102-015-0637-6.
[23] Liu NA, Araki T, Cuevas-Ramos D,et al. Cyclin E-mediated human proopiomelanocortin regulation as a therapeutic target for Cushing’s disease[J].J Clin Endocrinol Metab, 2015,100(7):2557-2564. DOI: 10.1210/jc.2015-1606.
[24] Meijer L, Borgne A, Mulner O,et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5[J].Eur J Biochem,1997,243(1-2):527-536.
[25] Keller-Wood ME, Dallman MF. Corticosteroid inhibition of ACTH secretion[J].Endocr Rev,1984,5(1):1-24.
[26] Riebold M, Kozany C, Freiburger L,et al. A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing’s disease[J].Nat Med, 2015,21(3):276-280. DOI: 10.1038/nm.3776.
[27] Freeman BC, Yamamoto KR. Disassembly of transcriptional regulatory complexes by molecular chaperones[J].Science, 2002,296(5576):2232-2235.DOI:10.1126/science.1073051.
[28] Kang KI, Meng X, Devin-Leclerc J,et al. The molecular chaperone Hsp90 can negatively regulate the activity of a glucocorticosteroid-dependent promoter[J].Proc Natl Acad Sci U S A,1999,96(4):1439-1444.
[29] Dahia PL, Ahmed-Shuaib A, Jacobs RA,et al. Vasopressin receptor expression and mutation analysis in corticotropin-secreting tumors[J].J Clin Endocrinol Metab,1996,81(5):1768-1771. DOI:10.1210/jcem.81.5.8626831.
[30] Luque RM, Ibá?ez-Costa A, López-Sánchez LM,et al. A cellular and molecular basis for the selective desmopressin-induced ACTH release in Cushing’s disease patients: key role of AVPR1b receptor and potential therapeutic implications[J].J Clin Endocrinol Metab,2013,98(10):4160-4169. DOI: 10.1210/jc.2013-1992.
[31] Tateno T, Izumiyama H, Doi M,et al. Differential gene expression in ACTH-secreting and non-functioning pituitary tumors[J].Eur J Endocrinol, 2007,157(6):717-724. DOI:10.1530/EJE-07-0428.

相似文献/References:

[1]倪文婧,徐书杭,刘超.2021年美国甲状腺学会关于甲状腺未分化癌管理指南解读:实践精准医学[J].国际内分泌代谢杂志,2022,42(02):161.[doi:10.3760/cma.j.cn121383-20211101-11002]
　Ni Wenjing,Xu Shuhang,Liu Chao..Interpretation of 2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer: era of individualized precision medicine[J].International Journal of Endocrinology and Metabolism,2022,42(06):161.[doi:10.3760/cma.j.cn121383-20211101-11002]
[2]陈诗颖,崔岱.未分化甲状腺癌新型分子靶向与免疫治疗的研究进展[J].国际内分泌代谢杂志,2023,43(02):96.[doi:10.3760/cma.j.cn121383-20220418-04045]
　Chen Shiying,Cui Dai..Research progress of novel molecular target therapy and immunotherapy for anaplastic thyroid cancer[J].International Journal of Endocrinology and Metabolism,2023,43(06):96.[doi:10.3760/cma.j.cn121383-20220418-04045]
[3]谢梦晨,郭洋洋,黄金慧,等.原发性醛固酮增多症基因型与临床表型关系的研究进展[J].国际内分泌代谢杂志,2023,43(03):216.[doi:10.3760/cma.j.cn121383-20220307-03015]
　Xie Mengchen,Guo Yangyang,Huang Jinhui,et al.Association of genotype and clinical phenotype of primary aldosteronism[J].International Journal of Endocrinology and Metabolism,2023,43(06):216.[doi:10.3760/cma.j.cn121383-20220307-03015]

备注/Memo

备注/Memo:
基金项目:中华医学会临床医学科研专项资金-下丘脑垂体研究项目(13050940479); 国家临床重点专科基金(WBYZ2011-873)
更新日期/Last Update: 2016-12-20